Markets

Regeneron's (REGN) Inmazeb Ebola Treatment Gets FDA Approval

Regeneron Pharmaceuticals, Inc. REGN announced that the FDA has approved its triple antibody cocktail, REGN-EB3, under the brand name, Inmazeb, for the treatment of the infection caused by Zaire ebolavirus in adult and pediatric patients. The patient population includes newborns of mothers who have tested positive for the infection.

Inmazeb (atoltivimab, maftivimab and odesivimab-ebgn) is a novel anti-viral antibody medicine.  The drug showed superiority compared to other investigational agents — ZMapp and Gilead Sciences’ GILD remdesivir — with respect to mortality in the PALM study.

Per Regeneron, this is the first time the FDA has approved a treatment specifically for Ebola.

Regeneron will deliver a significant number of Inmazeb treatment doses over the course of six years to the Biomedical Advanced Research and Development Authority (BARDA), as part of an agreement announced in July 2020.

We note that in December 2019, the FDA approved Merck’s MRK vaccine, Ervebo, for the prevention of Ebola in individuals 18 years of age and older.

Regeneron’s shares have surged 59.4% in the year so far compared with the industry’s growth of 1.8%.

 

The company has been in the news, of late, after its antibody treatment, REGN-COV2, for COVID-19 was hailed by President Donald Trump who was administered the same after he tested COVID-19 positive.

Regeneron submitted a request to the FDA for an Emergency Use Authorization (EUA) for REGN-COV2.

REGN-COV2's development and manufacturing have been funded in part with federal funds from BARDA. Regeneron has recently partnered with Roche RHHBY to increase the global supply of the candidate.

Currently, there are no FDA-approved treatments for the severe illness caused by SARS-CoV-2. The pharma/biotech sector is racing against time to come up with treatments and vaccines to cure the contagion. Given the alarming levels of the spread and severity of the pandemic, quite a few biotechs are developing antibodies or evaluating their approved drugs or pipeline candidates to determine if they are effective enough to treat the infected patients. The FDA earlier granted an EUA to remdesivir for the COVID-19 infection.

Regeneron currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
 
Roche Holding AG (RHHBY): Free Stock Analysis Report
 
Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
 
Merck Co., Inc. (MRK): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More